Compare Snowflake Inc (SNOW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs Twist Bioscience Corp — how do they compare? Snowflake Inc trades at $345.45 (market cap $121.15B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Snowflake Inc is far larger — about 12× Twist Bioscience Corp's market cap, and Snowflake Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Snowflake Inc for 54 Days and Twist Bioscience Corp for 27 Days on average.
| SNOW | TWST | |
|---|---|---|
Market Cap | $121.15B | $10.08B |
Volume | 3,986,549 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $356.47 | $205.00 |
52-Week Low | $121.11 | $25.45 |
Typical Hold Time | 54 Days | 27 Days |
Enterprise Value | $121.57B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $332.85, down 0.92% on the day, with technical indicators showing a neutral bias amid strong analyst support. The company demonstrates robust revenue growth, reaching $3.63 billion in 2025, but continues to post significant net losses (-$1.29 billion). Recent developments include a $3.75 billion convertible note offering and expanded partnerships, positioning the company for future growth in the AI data cloud market.
Snowflake presents a compelling growth story with strong revenue momentum and dominant market positioning, though profitability remains a key challenge. The stock offers 25% upside to the consensus price target of $418.03, supported by overwhelming analyst bullishness (81% buy ratings). However, investors face risks from ongoing losses, high valuation multiples, and competitive pressures in the cloud data sector.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
